We identified 990 citations related to advanced hepatocellular carcinoma; of these, 12 reported clinical trial results on tyrosine kinase/vascular endothelial growth factor (VEGF) inhibition plus programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibition combination in previously untreated patients (four phase 1b, one phase 1/2, six phase 3, one not indicated). Here, VEGFA is linked to hepatocellular carcinoma.